Search

Your search keyword '"Deane, Kevin D."' showing total 657 results
Start Over Author "Deane, Kevin D."
657 results on '"Deane, Kevin D."'

159. Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the Promoter Variant.

Author

Matson, Scott M., Deane, Kevin D., Peljto, Anna L., Bang, Tami J., Sachs, Peter B., Walts, Avram D., Collora, Christopher, Shuyu Ye, Demoruelle, M. Kristen, Humphries, Stephen M., Schwartz, David A., Lee, Joyce S., and Ye, Shuyu

Subjects
INTERSTITIAL lung diseases, RHEUMATOID arthritis, PULMONARY fibrosis, LONGITUDINAL method, RHEUMATOID arthritis risk factors, RESEARCH, GENETIC mutation, CLINICAL trials, RESEARCH methodology, EVALUATION research, COMPARATIVE studies, DISEASE susceptibility, GLYCOPROTEINS, DISEASE prevalence, GENETIC markers, RESEARCH funding, EARLY diagnosis, DISEASE complications
Abstract

In the article, the authors present their prospective study to determine the prevalence of and risk factors for subclinical interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). Also cited are the association of the MUC5B promoter variant with RA, and the qualitative findings of interstitial fibrosis.

Published
2022
Full Text
View/download PDF

163. Antibody Responses to Citrullinated and Non-Citrullinated Antigens in the Sputum of Subjects with and At-Risk for Rheumatoid Arthritis

Author

Demoruelle, M. Kristen, Bowers, Emily, Lahey, Lauren J., Sokolove, Jeremy, Purmalek, Monica, Seto, Nickie L., Weisman, Michael H., Norris, Jill M., Kaplan, Mariana J., Holers, V. Michael, Robinson, William H., and Deane, Kevin D.

Subjects
Adult, Male, Sputum, Middle Aged, Autoantigens, Extracellular Traps, Peptides, Cyclic, Article, Arthritis, Rheumatoid, Young Adult, Case-Control Studies, Antibody Formation, Humans, Citrullination, Female, Prospective Studies, Aged, Autoantibodies
Abstract

The location and mechanisms involved in the initial generation of autoantibodies to citrullinated and noncitrullinated proteins/peptides during the natural history of rheumatoid arthritis (RA) development is incompletely understood. This study sought to explore individual antibody responses to citrullinated and noncitrullinated proteins/peptides in the sputum and associations with neutrophil extracellular traps (NETs) in subjects at risk for the future development of RA.Serum and sputum samples were obtained from 41 RA-free subjects who were considered at risk for the development of RA based on familial or serologic risk factors, from 20 subjects classified as having RA, and from 22 healthy control subjects. Samples were evaluated using a bead-based array for IgG reactivity to 29 citrullinated proteins/peptides and 21 noncitrullinated proteins/peptides. Cutoff levels for antibody positivity were established in a separate control group. NET levels in the sputum were measured using sandwich enzyme-linked immunosorbent assays that quantitate DNA-myeloperoxidase and DNA-neutrophil elastase complexes.In at-risk subjects, antibody responses to the citrullinated forms of fibrinogen, apolipoprotein E, and fibronectin were highly prevalent. The most citrulline-specific antibodies in the sputum of at-risk subjects were those to fibrinogen, vimentin, and peptides of fibrinogen A and apolipoprotein A1. Patterns of sputum autoantibody positivity differed between at-risk subjects and subjects with RA. In at-risk subjects, increasing sputum NET levels significantly correlated with several citrullinated and some noncitrullinated antibody reactivities.These findings suggest that sputum antibody reactivity to particular citrullinated and noncitrullinated proteins/peptides is specific for RA and for subjects at risk of RA, and the association of these proteins/peptides with NETs may be a key feature of early RA-related autoimmunity in the lung. These results further support the hypothesis that the lung plays a role in early RA-related autoimmunity.

Published
2018

164. Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis

Author

Kelmenson, Lindsay B., primary, Wagner, Brandie D., additional, McNair, Bryan K., additional, Frazer‐Abel, Ashley, additional, Demoruelle, M. Kristen, additional, Bergstedt, Dylan T., additional, Feser, Marie L., additional, Moss, Laura K., additional, Parish, Mark C., additional, Mewshaw, Elizabeth A., additional, Mikuls, Ted R., additional, Edison, Jess D., additional, Holers, V. Michael, additional, and Deane, Kevin D., additional

Published
2019
Full Text
View/download PDF

166. Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody–Positive Patients Without Rheumatoid Arthritis

Author

Ford, Julia A., primary, Liu, Xinyi, additional, Marshall, Allison A., additional, Zaccardelli, Alessandra, additional, Prado, Maria G., additional, Wiyarand, Charlene, additional, Lu, Bing, additional, Karlson, Elizabeth W., additional, Schur, Peter H., additional, Deane, Kevin D., additional, and Sparks, Jeffrey A., additional

Published
2019
Full Text
View/download PDF

167. Unique Sjögren’s syndrome patient subsets defined by molecular features

Author

James, Judith A, primary, Guthridge, Joel M, primary, Chen, Hua, primary, Lu, Rufei, primary, Bourn, Rebecka L, primary, Bean, Krista, primary, Munroe, Melissa E, primary, Smith, Miles, primary, Chakravarty, Eliza, primary, Baer, Alan N, primary, Noaiseh, Ghaith, primary, Parke, Ann, primary, Boyle, Karen, primary, Keyes-Elstein, Lynette, primary, Coca, Andreea, primary, Utset, Tammy, primary, Genovese, Mark C, primary, Pascual, Virginia, primary, Utz, Paul J, primary, Holers, V. Michael, primary, Deane, Kevin D, primary, Sivils, Kathy L, primary, Aberle, Teresa, primary, Wallace, Daniel J, primary, McNamara, James, primary, Franchimont, Nathalie, primary, and St. Clair, E. William, primary

Published
2019
Full Text
View/download PDF

168. Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease

Author

England, Bryant R., primary, Duryee, Michael J., additional, Roul, Punyasha, additional, Mahajan, Tina D., additional, Singh, Namrata, additional, Poole, Jill A., additional, Ascherman, Dana P., additional, Caplan, Liron, additional, Demoruelle, M. Kristen, additional, Deane, Kevin D., additional, Klassen, Lynell W., additional, Thiele, Geoffrey M., additional, and Mikuls, Ted R., additional

Published
2019
Full Text
View/download PDF

170. SAT0082 ASSOCIATIONS OF BASELINE CLINICAL AND BIOMARKER FACTORS WITH SYMPTOMS AND FUTURE DEVELOPMENT OF CLINICALLY-APPARENT RHEUMATOID ARTHRITIS IN AN ACPA POSITIVE COHORT

Author

Deane, Kevin D., primary, Nagpal, Sunil, additional, Rao, Navin, additional, Baribaud, Frederic, additional, Vratsanos, George, additional, James, Eddie A., additional, Buckner, Jane H., additional, Firestein, Gary S., additional, Boyle, David L., additional, Posso, Sylvia, additional, Robinson, William H., additional, Moss, Laurie K., additional, Barzideh, Saman, additional, Polinski, Kristen, additional, Ivanov, Sergei, additional, Seifert, Jennifer, additional, and Michael Holers, V., additional

Published
2019
Full Text
View/download PDF

171. Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: A randomized controlled trial

Author

Marshall, Allison A., primary, Zaccardelli, Alessandra, additional, Yu, Zhi, additional, Prado, Maria G., additional, Liu, Xinyi, additional, Miller Kroouze, Rachel, additional, Kalia, Sarah S., additional, Green, Robert C., additional, Triedman, Nellie A., additional, Lu, Bing, additional, Deane, Kevin D., additional, Iversen, Maura D., additional, Karlson, Elizabeth W., additional, and Sparks, Jeffrey A., additional

Published
2019
Full Text
View/download PDF

172. Anticyclic Citrullinated Peptide Antibodies 3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis

Author

Berens, Heather M., primary, Polinski, Kristen J., additional, Mikuls, Ted R., additional, Khatter, Sonia, additional, August, Justin, additional, Visser, Ashley, additional, Mahler, Michael, additional, Weisman, Michael H., additional, O’Dell, James R., additional, Keating, Richard M., additional, Buckner, Jane H., additional, Gregersen, Peter K., additional, Norris, Jill M., additional, Holers, V. Michael, additional, Deane, Kevin D., additional, and Demoruelle, M. Kristen, additional

Published
2019
Full Text
View/download PDF

173. Striking a balance in rheumatoid arthritis prevention trials

Author

O’Neil, Liam J. and Deane, Kevin D.

Abstract

The discovery that autoantibodies and other factors can predict the future onset of rheumatoid arthritis (RA) has encouraged the development of clinical trials looking at RA prevention. Although an exciting area of research, finding an approach that results in the successful completion of an RA prevention trial is challenging.

Published
2024
Full Text
View/download PDF

174. Triple positivity for anti–citrullinated protein autoantibodies, rheumatoid factor, and anti–carbamylated protein antibodies conferring high specificity for rheumatoid arthritis : implications for very early identification of at‐risk individuals

Author

Verheul, Marije K., Böhringer, Stefan, van Delft, Myrthe A. M., Jones, Jonathan D., Rigby, William F. C., Gan, Ryan W., Holers, V. Michael, Edison, Jess D., Deane, Kevin D., Janssen, Koen M. J., Westra, Johanna, Brink, Mikael, Rantapää-Dahlqvist, Solbritt, Huizinga, Tom W. J., van der Helm-van Mil, Annette H. M., van der Woude, Diane, Toes, Rene E. M., Trouw, Leendert A., Verheul, Marije K., Böhringer, Stefan, van Delft, Myrthe A. M., Jones, Jonathan D., Rigby, William F. C., Gan, Ryan W., Holers, V. Michael, Edison, Jess D., Deane, Kevin D., Janssen, Koen M. J., Westra, Johanna, Brink, Mikael, Rantapää-Dahlqvist, Solbritt, Huizinga, Tom W. J., van der Helm-van Mil, Annette H. M., van der Woude, Diane, Toes, Rene E. M., and Trouw, Leendert A.

Abstract

OBJECTIVE: In rheumatoid arthritis(RA), the autoantibodies anti-citrullinated protein antibodies(ACPA) and rheumatoid factor(RF) are commonly used to aid RA diagnosis. Although these autoantibodies are mainly found in RA, their specificity is not optimal. It is therefore difficult to identify RA patients, especially in very early disease, based on the presence of ACPA and RF alone. Also, anti-carbamylated protein(anti-CarP) antibodies have diagnostic and prognostic value as the presence of anti-CarP antibodies associates with joint damage in RA patients and with future RA development in arthralgia patients. Therefore, we aimed to investigate the value of combined antibody testing in relation to prediction and diagnosis of (early) RA. METHODS: A literature search resulted in twelve studies, consisting of RA patients, pre-RA individuals, disease controls, healthy first-degree relatives of RA patients or healthy controls, in which data on RF, ACPA and anti-CarP antibody-status was available. Random effects meta-analyses were carried out for several antibody combinations. RESULTS: The individual antibodies are highly prevalent in RA(34%-80%) compared to the control groups, but are also present in non-RA controls(0%-23%). To classify most people correctly as RA or non-RA, the combination of ACPA and/or RF often performs well(specificity:65-100, sensitivity:59-88). However, triple positivity for ACPA, RF and anti-CarP antibodies results in a higher specificity(98-100) (accompanied by a lower sensitivity(11-39)). CONCLUSIONS: As the rheumatology field is moving towards very early identification of RA and possible screening for individuals at maximum risk in populations with a low pre-test probability, triple positivity provides interesting information on individuals at risk to develop RA.

Published
2018
Full Text
View/download PDF

175. Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift.

Author

Deane, Kevin D. and Holers, V. Michael

Subjects
*RHEUMATOID arthritis diagnosis, *RHEUMATOID arthritis risk factors, *RHEUMATOID arthritis treatment, *ATTITUDE (Psychology), *MEDICAL personnel, *MEDICAL research, *PUBLIC health, *RHEUMATOID arthritis, *RISK assessment
Abstract

Rheumatoid arthritis (RA) is currently diagnosed and treated when an individual presents with signs and symptoms of inflammatory arthritis (IA) as well as other features, such as autoantibodies and/or imaging findings, that provide sufficient confidence that the individual has RA‐like IA (e.g., meeting established classification criteria) that warrants therapeutic intervention. However, it is now known that there is a stage of seropositive RA during which circulating biomarkers and other factors (e.g., joint symptoms) can be used to predict if and when an individual who does not currently have IA may develop future clinically apparent IA and classifiable RA. Indeed, the discovery of the "pre‐RA" stage of seropositive disease has led to the development of several clinical trials in which individuals are studied to identify ways to delay or prevent the onset of clinically apparent IA/RA. This review focuses on several issues pertinent to understanding the prevention of RA. These include discussion of the pathogenesis of pre‐RA development, prediction of the likelihood and timing of future classifiable RA, and a review of completed and ongoing clinical trials in RA prevention. Furthermore, this review discusses challenges and opportunities to be addressed to effect a paradigm shift in RA, where in the near future, proactive risk assessment focused on prevention of RA will become a public health strategy in much the same manner as cardiovascular disease is managed today. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

176. Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting.

Author

Bemis, Elizabeth A., Demoruelle, M. Kristen, Seifert, Jennifer A., Polinski, Kristen J., Weisman, Michael H., Buckner, Jane H., Gregersen, Peter K., Mikuls, Ted R., ODell, James R., Keating, Richard M., Deane, Kevin D., Holers, V. Michael, and Norris, Jill M.

Subjects
AUTOANTIBODIES, DISEASE progression, RESEARCH, RESEARCH methodology, MEDICAL screening, GENETIC testing, EVALUATION research, MEDICAL cooperation, COMPARATIVE studies, RHEUMATOID arthritis, DISEASE susceptibility, RESEARCH funding, GENETIC techniques, LONGITUDINAL method, GENEALOGY
Abstract

Objectives: Little is known about the likelihood of developing inflammatory arthritis (IA) in individuals who screen autoantibody positive (aAb+) in a non-clinical research setting.Methods: We screened for serum cyclic citrullinated peptide antibody (anti-CCP) and rheumatoid factor isotype aAbs in subjects who were at increased risk for rheumatoid arthritis (RA) because they are a first-degree relative of an individual with classified RA (n=1780). We evaluated combinations of aAbs and high titre aAbs, as defined by 2-times (2 x) the standard cut-off and an optimal cut-off, as predictors of our two outcomes, aAb+ persistence and incident IA.Results: 304 subjects (17.1%) tested aAb+; of those, 131 were IA-free and had at least one follow-up visit. Sixty-four per cent of these tested aAb+ again on their next visit. Anti-CCP+ at levels ≥2 x the standard cut-off was associated with 13-fold higher likelihood of aAb +persistence. During a median of 4.4 years (IQR: 2.2-7.2), 20 subjects (15.3%) developed IA. Among subjects that screened anti-CCP+ at ≥ 2 x or ≥an optimal cut-off, 32% and 26% had developed IA within 5 years, respectively. Both anti-CCP cut-offs conferred an approximate fourfold increased risk of future IA (HR 4.09 and HR 3.95, p<0.01).Conclusions: These findings support that aAb screening in a non-clinical setting can identify RA-related aAb+ individuals, as well as levels and combinations of aAbs that are associated with higher risk for future IA. Monitoring for the development of IA in aAb+ individuals and similar aAb testing approaches in at-risk populations may identify candidates for prevention studies in RA. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

177. Estrogens regulate glycosylation of immunoglobulin G in women and men

Author

Ercan, Altan, Kohrt, Wendy, Cui, Jing, Deane, Kevin D., Pezer, Marija, Yu, Elaine W., Hausmann, Jonathan S., Campbell, Harry, Kaiser, Ursula B., Rudd, Pauline M., Lauc, Gordan, Wilson, James F., Finkelstein, Joel S., and Nigrovic, Peter A.

Subjects
immunoglobulin G, glycosylation, estrogen, immunity
Abstract

The immunologic potency of immunoglobulin G is modulated by glycosylation, but mechanisms regulating this process are undefined. A role for sex hormones is suggested by differences in IgG glycans between women and men, most prominently with respect to galactose content. We therefore assessed IgG galactosylation in 713 healthy adults from 2 cohorts, as well as in 159 subjects from 4 randomized controlled studies of endocrine manipulation: postmenopausal women receiving conjugated estrogens, raloxifene or placebo ; premenopausal women deprived of gonadal hormones with leuprolide and treated with estradiol or placebo ; men deprived of gonadal hormones with goserelin and given testosterone or placebo ; and men treated comparably together with anastrozole to block conversion of testosterone to estradiol. Menopause was associated with an increase in agalactosylated IgG glycans, particularly in the most abundant fucosylated non-bisected (G0F) glycoform. Conjugated estrogens and raloxifene reduced G0F in postmenopausal women, while in premenopausal women leuprolide increased G0F in a manner reversed by estradiol. Among men, goserelin increased G0F, an effect blocked by testosterone through conversion to estradiol. These results establish estrogens as an in vivo modulator of IgG galactosylation in both women and men, defining a new pathway by which sex modulates immunity.

Published
2017

178. Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis.

Author

Kelmenson, Lindsay B., Wagner, Brandie D., McNair, Bryan K., Frazer‐Abel, Ashley, Demoruelle, M. Kristen, Bergstedt, Dylan T., Feser, Marie L., Moss, Laura K., Parish, Mark C., Mewshaw, Elizabeth A., Mikuls, Ted R., Edison, Jess D., Holers, V. Michael, and Deane, Kevin D.

Subjects
AUTOANTIBODIES, BIOTHERAPY, IMMUNOGLOBULINS, KERATOCONJUNCTIVITIS sicca, LUNG diseases, RHEUMATOID arthritis, DISEASE prevalence, CASE-control method, DESCRIPTIVE statistics
Abstract

Objective: To evaluate patterns of elevations of isotypes of rheumatoid factor (RF) and anti–citrullinated protein antibodies (ACPAs) pre–rheumatoid arthritis (RA) diagnosis and post–RA diagnosis. Methods: Using the Department of Defense Serum Repository we identified 214 RA cases and 210 matched controls. Up to 3 pre–RA diagnosis and 1 post–RA diagnosis serum samples per subject were tested for RF and for IgA, IgG, and IgM ACPAs. The timing and trajectories of elevations of autoantibodies were evaluated. Results: Autoantibody levels were elevated in cases versus controls a mean of 17.9 years before RA diagnosis for IgG ACPA, 14.2 years for IgA‐RF, 7.2 years for IgM‐RF, 6.2 years for IgA ACPA, and 5.0 years for both IgM ACPA and IgG‐RF (P < 0.01 for all comparisons). There were similar relationships for positive or negative autoantibody status, with cases first showing positivity for IgG ACPA 1.9 years pre‐RA and for IgA‐RF 1.7 years pre‐RA, followed by the other isotypes. Only IgA ACPA positivity was significantly increased in post–RA diagnosis samples (19% 0–2 years pre‐RA versus 39% >2 years post–RA diagnosis; P = 0.04). All autoantibody levels demonstrated an early initial elevation, a period of stability, then an increase immediately before RA diagnosis. A pre‐RA endotype of early elevation of autoantibodies was associated with increased use of biologic therapy, and a higher prevalence of sicca symptoms and lung disease post–RA diagnosis. Conclusion: Differences in patterns of elevations of autoantibody isotypes have implications for understanding the pathophysiology of RA development. These include understanding what factors drive initial autoantibody elevations compared to what factors (including mucosal) drive later increases in autoantibody levels and a transition to clinically apparent RA, and how pre‐RA endotypes may influence post–RA diagnosis phenotypes. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

180. Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis

Author

Verheul, Marije K., primary, Böhringer, Stefan, additional, Delft, Myrthe A. M., additional, Jones, Jonathan D., additional, Rigby, William F. C., additional, Gan, Ryan W., additional, Holers, V. Michael, additional, Edison, Jess D., additional, Deane, Kevin D., additional, Janssen, Koen M. J., additional, Westra, Johanna, additional, Brink, Mikael, additional, Rantapää‐Dahlqvist, Solbritt, additional, Huizinga, Tom W. J., additional, Helm‐van Mil, Annette H. M., additional, Woude, Diane, additional, Toes, Rene E. M., additional, and Trouw, Leendert A., additional

Published
2018
Full Text
View/download PDF

181. Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial

Author

Sparks, Jeffrey A., primary, Iversen, Maura D., additional, Yu, Zhi, additional, Triedman, Nellie A., additional, Prado, Maria G., additional, Miller Kroouze, Rachel, additional, Kalia, Sarah S., additional, Atkinson, Michael L., additional, Mody, Elinor A., additional, Helfgott, Simon M., additional, Todd, Derrick J., additional, Dellaripa, Paul F., additional, Bermas, Bonnie L., additional, Costenbader, Karen H., additional, Deane, Kevin D., additional, Lu, Bing, additional, Green, Robert C., additional, and Karlson, Elizabeth W., additional

Published
2018
Full Text
View/download PDF

182. Antibody Responses to Citrullinated and Noncitrullinated Antigens in the Sputum of Subjects With Rheumatoid Arthritis and Subjects at Risk for Development of Rheumatoid Arthritis

Author

Demoruelle, M. Kristen, primary, Bowers, Emily, additional, Lahey, Lauren J., additional, Sokolove, Jeremy, additional, Purmalek, Monica, additional, Seto, Nickie L., additional, Weisman, Michael H., additional, Norris, Jill M., additional, Kaplan, Mariana J., additional, Holers, V. Michael, additional, Robinson, William H., additional, and Deane, Kevin D., additional

Published
2018
Full Text
View/download PDF

183. Contributors

Author

Akuthota, Venu, Alonso, Itziar Quinzaños, Anderson, Marsha S., Arroyo, Ramon A., Afzal, Wais, Bath, Amrita, Battafarano, Daniel F., Berney, Seth Mark, Brasington, Richard, Cannella, Amy C., Caplan, Liron, Crayne, Courtney B., Cron, Randy Q., Damioli, Laura, Davis, Lisa, Deane, Kevin D., Demoruelle, Kristen, Dixon, Stacy, Dominguez, Samuel R., Eckhoff, Donald G., Erickson, Alan R., Feely, Michael G., Fischer, Aryeh, Fuhllbrigge, Robert C., Garnett, Alexandra, Gizinski, Alison M., Griffith, Melissa, Griffith, Rebecca, Hill, Erica M., Jesse, Mary K., Johnson, Steven C., Kasperbauer, Shannon, Kelmenson, Lindsay, Kolfenbach, Jason R., Kota, Vinisha, Kuhn, Kristine A., Kumar, Bharat, Lai, Jamie, Lawrence-Wolff, Katrina M., Lin, Tiffany, Louie, James S., McDermott, Michael T., McKown, Kevin, Mikuls, Ted R., Moore, Katharine F., Palestine, Alan G., Pearson, Duane, Quan, Dianna, Shirley, Joel Brian, Singh, Namrata, Snow, Marcus H., Stichman, Jennifer, Truong, Tho, Tyler, Kim Nguyen, Strickland, Colin, Striebich, Christopher C., Swanson, Christine M., Tofferi, Jeanne K., Vidal, Armando F., Vogelgesang, Scott, Wahl, Matthew P., Weinstein, Elena, West, Matthew S., West, Sterling G., Wicklund, Matthew, Wood, Patrick R., and Zell, JoAnn

Published
2020
Full Text
View/download PDF

184. IgA Plasmablasts are Elevated in Subjects At Risk for Future Rheumatoid Arthritis

Author

Kinslow, Jennifer D., Blum, Lisa K., Deane, Kevin D., Demoruelle, M. Kristen, Okamoto, Yuko, Parish, Mark, Kongpachith, Sarah, Lahey, Lauren J., Norris, Jill M., Robinson, William H., and Holers, V. Michael

Subjects
Arthritis, Rheumatoid, Immunoglobulin M, Rheumatoid Factor, Immunoglobulin G, Humans, Article, Immunoglobulin A
Published
2016

188. Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study

Author

Birru Talabi, Mehret, primary, Mackey, Rachel H., additional, Kuller, Lewis H., additional, Dorman, Janice S., additional, Deane, Kevin D., additional, Robinson, William H., additional, Walitt, Brian T., additional, Chang, Yuefang, additional, Holers, V. Michael, additional, Liu, Simin, additional, and Moreland, Larry W., additional

Published
2017
Full Text
View/download PDF

189. Anti–Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients

Author

Demoruelle, M. Kristen, primary, Harrall, Kylie K., additional, Ho, Linh, additional, Purmalek, Monica M., additional, Seto, Nickie L., additional, Rothfuss, Heather M., additional, Weisman, Michael H., additional, Solomon, Joshua J., additional, Fischer, Aryeh, additional, Okamoto, Yuko, additional, Kelmenson, Lindsay B., additional, Parish, Mark C., additional, Feser, Marie, additional, Fleischer, Chelsie, additional, Anderson, Courtney, additional, Mahler, Michael, additional, Norris, Jill M., additional, Kaplan, Mariana J., additional, Cherrington, Brian D., additional, Holers, V. Michael, additional, and Deane, Kevin D., additional

Published
2017
Full Text
View/download PDF

192. Estrogens regulate glycosylation of IgG in women and men

Author

Ercan, Altan, primary, Kohrt, Wendy M., additional, Cui, Jing, additional, Deane, Kevin D., additional, Pezer, Marija, additional, Yu, Elaine W., additional, Hausmann, Jonathan S., additional, Campbell, Harry, additional, Kaiser, Ursula B., additional, Rudd, Pauline M., additional, Lauc, Gordan, additional, Wilson, James F., additional, Finkelstein, Joel S., additional, and Nigrovic, Peter A., additional

Published
2017
Full Text
View/download PDF

194. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis

Author

Solomon, Joshua J., Matson, Scott, Kelmenson, Lindsay B., Chung, Jonathan H., Hobbs, Stephen B., Rosas, Ivan O., Dellaripa, Paul F., Doyle, Tracy J., Poli, Sergio, Esposito, Anthony J., Visser, Ashley, Marin, A. Itzam, Amigues, Isabelle, Fernández Pérez, Evans R., Brown, Kevin K., Mahler, Michael, Heinz, David, Cool, Carlyne, Deane, Kevin D., Swigris, Jeffrey J., and Demoruelle, M. Kristen

Abstract

The etiology of idiopathic pulmonary fibrosis (IPF) is unknown. Because it shares genetic, histopathologic, and radiographic features with the fibrosing interstitial lung disease seen in rheumatoid arthritis (RA), the goal of this study was to investigate RA-related autoantibodies in IPF.

Published
2020
Full Text
View/download PDF

195. Interstitial lung abnormalities in patients with early rheumatoid arthritis: A pilot study evaluating prevalence and progression.

Author

Huawei Dong, Julien, Peter J., Demoruelle, M. Kristen, Deane, Kevin D., and Weisman, Michael H.

Subjects
OBSTRUCTIVE lung diseases, RHEUMATOID arthritis, HUMAN abnormalities, PILOT projects, C-reactive protein, LUNGS
Abstract

Objective: Pulmonary disease is a leading cause of morbidity and mortality in rheumatoid arthritis (RA). In this study, we investigated the prevalence and progression of interstitial lung abnormalities (ILA) in a prospective cohort study of 18 subjects with early RA. Methods: Eighteen adults diagnosed with anti-citrullinated protein-antibody-positive RA within the prior year underwent baseline high-resolution computed tomography (HRCT), symptom assessment, and pulmonary function and laboratory testing. The follow-up HRCT and clinical assessment were completed after 1 year. Results: Seven of the 18 patients (39%) had baseline HRCT abnormalities including septal thickening, honeycombing, ground glass opacities, and/or traction bronchiectasis. At follow-up, 6 out of the 7 subjects (86%) with ILAs at baseline exhibited progression, while 10 out of 11 (91%) without ILAs at baseline remained stable. A higher Clinical Chronic Obstructive Pulmonary Disease Questionnaire score was associated with both the presence and progression of HRCT abnormalities (10 vs 2, p=0.045; 10 vs 2, p=0.009, respectively). C-reactive protein (CRP) trended higher in patients with radiologic abnormalities (3.5 mg/L vs 1.1 mg/L, p=0.08) and was significantly higher in those with progression (3.5 mg/L vs 1 mg/L, p=0.024). Smoking, pulmonary function, and autoantibodies were not associated with HRCT abnormalities. Conclusion: ILAs are prevalent in patients with early RA. If identified at baseline, radiographic progression of ILAs after 1 year is likely, while those without ILAs at baseline are unlikely to develop new ILAs. In addition, early respiratory symptoms and higher CRP levels may correlate with the presence and progression of underlying ILAs. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

197. Airways Abnormalities in a Prospective Cohort of Patients With Rheumatoid Arthritis

Author

Matson, Scott M., Choi, Jiwoong, Rorah, Drayton, Khan, Shamir, Trofimoff, Anna, Kim, Taewon, Lee, David H., Abdolijomoor, Asma, Chen, Maggie, Azeem, Imaan, Ngo, Linh, Bang, Tami J., Sachs, Peter, Deane, Kevin D., Demoruelle, M. Kristen, Castro, Mario, and Lee, Joyce S.

Abstract

Rheumatoid arthritis (RA) affects roughly 1% of the population and commonly involves the lungs. Of lung involvement in RA, interstitial lung disease (ILD) is well known; however, airways disease in RA is relatively understudied.

Published
2024
Full Text
View/download PDF

198. A comparison of anti-cyclic citrullinated peptides (CCP3 and CCP3.1) autoantibody tests in rheumatoid arthritis

Author

Nelson, Heather A., Banerjee, Dipanwita, Novis, Camille L., Deane, Kevin D., Feser, Marie L., and Nandakumar, Vijayalakshmi

Abstract

Anti-citrullinated protein antibodies (ACPA) are a specific serological biomarker used in the diagnosis of rheumatoid arthritis (RA). In clinical practice ACPA can be identified using immunoassays targeting synthetic cyclic citrullinated peptides (CCP). The 3rd generation anti-CCP IgG antibody (CCP3) offers improved sensitivity compared to the earlier versions. Recently, CCP3.1, capable of detecting both IgG and IgA antibodies, was introduced to enhance sensitivity, especially in patients with early RA.

Published
2024
Full Text
View/download PDF

199. Contributors

Author

Abelson, Abby G., Abramson, Steven B., Adachi, Jonathan D., Adams, Michael A., Aggarwal, Rohit, Aigner, Thomas, Akira, Shizuo, Albert, Daniel A., Aletaha, Daniel, Alevizos, Ilias, Allem, Kavitta B., Almehthel, Mohammed, Almohaya, Mohamed, Alonso, Elena Riera, Amigo, Mary-Carmen, Arden, Nigel K., Aringer, Martin, Arkema, Elizabeth V., Ascherman, Dana P., Atamas, Sergei P., Atkinson, Timothy J., Azeez, Maha A., Azevedo, Pedro M., Baer, Alan N., Baeten, Dominique, Baines, Colin P., Balsa, Alejandro, Baraliakos, Xenofon, Bardin, Thomas, Barnes, Jammie K., Barnsley, Les, Barr, Andrew J., Bathon, Joan M., Bauch, Angela, Bay-Jensen, Anne-Christine, Belch, Jill J.F., Bellamy, Nicholas, Bellido, Teresita, Benjamin, Michael, Bennell, Kim L., Beresford, Michael W., Berman, Brian, Bermas, Bonnie L., Bertsias, George, Bhalla, Sonal, Bilginer, Yelda, Birnbaum, Julius, Bleasel, Jane F., Block, Joel A., Blom, Ashley W., Böhm, Markus, Bonelli, Michael, Borchert, Grace, Boros, Christina A., Boumpas, Dimitrios T., Bozec, Aline, Brasington, Richard D., Jr., Braun, Jürgen, Brouwer, Elisabeth, Brown, Jacques P., Brown, Matthew A., Bruce, Ian N., Buch, Maya H., Buckley, Christopher D., Bugbee, William D., Burmester, Gerd-Rüdiger, Burns, Jane C., Burr, David B., Buttgereit, Frank, Bykerk, Vivian P., Calabrese, Leonard H., Callen, Jeffrey P., Carr, Andrew J., Carroll, Graeme J., Cavallo, Sabrina, Cervera, Ricard, Chaudhary, Prateek, Choi, Hyon K., Choy, Ernest H., Christopher-Stine, Lisa, Chu, Alvina D., Chung, Lorinda, Ciccia, Francesco, Clauw, Daniel J., Clinch, Jacqui, Clowse, Megan E.B., Coghlan, J. Gerard, Colbert, Robert A., Conaghan, Philip G., Cooper, Cyrus, Cooper, Robert G., Costenbader, Karen H., Cox, George L.D., Creamer, Paul, Cronstein, Bruce N., Cross, Raymond, Cutolo, Maurizio, D’Adamo, Chris, D’Agati, Vivette D., Daikh, David I., Dakin, Stephanie G., Dalbeth, Nicola, Davis, Aileen M., D’Cruz, David P., Ceulaer, Karel De, Rheum, Dipl, de Jesus, Adriana A., De Vita, Salvatore, de Wit, Maarten, Deal, Chad L., Deane, Kevin D., Dellaripa, Paul F., Dennison, Elaine, Denton, Christopher P., Dieppe, Paul, Dolan, Patricia, Doyle, Tracy J., Dyer, George S.M., Emery, Paul, Espinosa, Gerard, Espinoza, Luis R., Eyre, Stephen, Fanouriakis, Antonis C., Farber, Joshua, Fasth, Anders, Feist, Eugen, Feldman, Candace H., Feldman, Debbie, Filer, Andrew, Fiorentino, David F., Fisher, Benjamin A., Fisk, John D., Flores, Raymond H., Forbess, Lindsy, Fox, David A., Freemont, Anthony J., Fricka, Kevin B., Gabay, Cem, Gadina, Massimo, Gandolfo, Saviana, Gauntlett-Gilbert, Jeremy, Gay, Steffen, Gensler, Lianne S., Gerlag, Danielle M., Gold, Garry E., Goldbach-Mansky, Raphaela, Goldingay, Sarah J., Gómez-Puerta, José A., Goodman, Susan M., Gordon, Caroline, Gordon, Sharon M., Gorodkin, Rachel, Görtz, Simon, Grainger, Andrew J., Gravallese, Ellen M., Greenberg, Jeffrey D., Grieve, Sharon, Guilherme, Luiza, Gül, Ahmet, Gupta, Sarthak, Hagan, Matilda, Hagley, Karlene, Han, Shuhong, Hanly, John G., Hanson, Eric P., Haraoui, Boulos, Hardcastle, Sarah A., Harley, John B., Haroun, Tayseer G., Hashkes, Philip J., Hassan, Andrew Bassim, Haupt, Lukas, Hawker, Gillian A., Hawkins, Philip N., Heeringa, Peter, Heiberg, Turid, Heinegård, Dick, Helfgott, Simon M., Henriksen, Kim, Hinman, Rana S., Ho, Pauline Y.P., Hochberg, Marc C., Hoffmann, Markus H., Holick, Michael F., Holroyd, Christopher R., Holt, Cathy, Huizinga, Thomas W.J., Husni, M. Elaine, Inman, Robert D., Inoue, Dai, Isaac, Zacharia, Isaacs, John D., Iversen, Maura D., Jabs, Douglas A., Jaimungal, Sarada, James, Judith A., Javaid, M. Kassim, Javidan, Pooya, Javier, Rose-Marie, Jefferis, Roy, Johnsen, Alyssa K., Jordan, Joanne M., Joyce, Andrew A., Jung, Michelle, Kado, Ruba, Kaisho, Tsuneyasu, Kallenberg, Cees G.M., Kane, David, Kaplan, Mariana J., Karsdal, Morten Asser, Kassimos, Dimitrios G., Kastner, Daniel L., Kawano, Mitsuhiro, Kay, Jonathan, Keating, Richard M., Kelly, Jennifer A., Kendler, David, Khamashta, Munther A., Khan, Irfan R., Khanna, Dinesh, Klokkerud, Mari, Kolstad, Kathleen D., Kottyan, Leah, Kraus, Virginia Byers, Kvien, Tore K., Lafyatis, Robert, Landewé, Robert B.M., Langford, Carol A., Lau, Arthur N., Lavin, Robert A., Laxer, Ronald M., Learch, Thomas J., Leatherwood, Cianna, Lewis, Jennifer S., Lewith, George, Liao, Katherine P., Lightfoot, Adam P., Littlejohn, Geoffrey O., Lorenzo, Pilar, Lories, Rik J.U., Luger, Thomas A., Lundberg, Ingrid E., Luqmani, Raashid A., Lythgoe, Hanna M., MacDougall, Kristin J., MacKenzie, C. Ronald, Manasson, Julia, Mangham, David Charles, Mao, Rong, March, Lyn M., Marqués, Alejandro Olivé, Márquez, Javier, Martín-Mola, Emilio, Martínez-Lavín, Manuel, Matteson, Eric L., Matzat, Stephen J., Mayes, Maureen D., McAlindon, Timothy, McCabe, Candy S., McCarthy, Edward F., McCarthy, Geraldine M., McDermott, Michael F., McGonagle, Dennis, McLean, Lachy, Ian Melville, Andrew Robert, Michou, Laëtitia, Middleton, Rob, Mikdashi, Jamal A., Miller, Frederick W., Miller, Paul D., Minden, Kirsten, Miner, Jonathan J., Moe, Rikke Helene, Möller, Ingrid, Monach, Paul A., Mons, Barend, Myasoedova, Elena, Nam, Jackie L., Namur, Gauthier, Naredo, Esperanza, Neerinckx, Barbara, Nelson, Amanda E., Nicolson, Philippa J.A., Nieves, César E. Fors, Nordal, Ellen B., Nöth, Ulrich, Ntatsaki, Eleana, Oddis, Chester V., Omar, Ahmed, Ombrello, Michael J., Omisade, Antonina, Ong, Voon H., Önnerfjord, Patrik, Orcel, Philippe, Orr, Carl, O'Shea, John J., Ospelt, Caroline, Özen, Seza, Parker, Matthew J.S., Patrono, Carlo, Pilkington, Clarissa A., Pillinger, Michael H., Pineda, Carlos, Pipitone, Nicolò, Poddubnyy, Denis, Pope, Janet E., Postolova, Anna, Price, Andrew, Quartuccio, Luca, Rackwitz, Lars, Radner, Helga, Raychaudhuri, Soumya, Redmond, Anthony C., Rees, Jonathan L., Reeves, Westley H., Rehaume, Linda M., Remmers, Elaine F., Requena, Luis, Reynolds, Gary, Ribbens, Clio, Richards, Bethan, Richardson, Bruce C., Richette, Pascal, Richter, Adrian, Ritchlin, Christopher T., Ritter, Susan Y., Robinson, William H., Rogers, Valerie, Rosas, Ivan O., Rosenthal, Ann K., Rowan, Andrew D., Rudwaleit, Martin, Rull, Marina, Rygg, Marite, Saag, Kenneth G., Salmon, Jane E., Salter, Donald M., Salvarani, Carlo, Sandell, Linda J., Sandigursky, Sabina, Saxne, Tore, Schaible, Hans-Georg, Scher, Jose U., Schett, Georg, Schiffenbauer, Adam I., Schiller, Alan L., Schlesinger, Naomi, Schreiber, Benjamin E., Schwartz, Daniella Muallem, Shapiro, Lauren M., Sharma, Leena, Siaton, Bernadette C., Siegel, Richard M., Sieper, Joachim, Simard, Julia Fridman, Simmons, Barry P., Simms, Robert W., Singer, Nora G., Smith, Judith A., Smith, Stacy E., Smolen, Josef S., Solomon, Daniel H., Stack, John, Stanley, David, Steen, Virginia D., Steere, Allen C., Steiner, Günter, Steinert, Andre F., Stojan, George, Strand, Vibeke, Straub, Rainer H., Streeten, Elizabeth A., Superti-Furga, Giulio, Tak, Paul P., Tang, Chen, Taylor, Peter C., Terkeltaub, Robert, Thomas, Beje, Thomas, Ranjeny, Thorne, Jennifer E., Tobias, Jonathan H., Tremoulet, Adriana H., Trouw, Leendert A., Tuan, Rocky S., Turesson, Carl, Umehara, Hisanori, Valdes, Ana M., van der Heijde, Désirée, van Vollenhoven, Ronald F., Vanderstukken, Joke, Varga, John, Vassilopoulos, Dimitrios, Veale, Douglas J., Viatte, Sebastien, Vincent, Tonia, Vital, Edward M., von Loga, Isabell S., Wallace, Daniel J., Walsh, Nicola, Warber, Sara L., Warburton, Gary, Ward, Robert J., Watts, Laura, Watts, Richard A., Wedderburn, Lucy R., Weinblatt, Michael E., Weir, Matthew R., Sr., Weisman, Michael H., Weiss, Pamela F., Wenham, Claire Y.J., West, Sterling G., White, Harriet Branford, White, Kenneth E., Wilkinson, David J., Williams, David E., Williams, Richard, Wilson, Hannah, Winthrop, Kevin L., Witt, Claudia M., Witzmann, Gerhard, Wong, John B., Woolf, Anthony D., Wordsworth, Paul B., Worthington, Jane, Wysham, Katherine D., Xu, Huji, Young, David A., Young, Stephen P., Yusof, Md Yuzaiful Md, Zhuang, Haoyang, and Zink, Angela

Published
2019
Full Text
View/download PDF

200. Prevention of Rheumatic Diseases: Strategies, Caveats and Future Directions

Author

Finckh, Axel and Deane, Kevin D

Subjects
ddc:616, Primary Prevention, Early Diagnosis, Antirheumatic Agents, Early Medical Intervention, Rheumatic Diseases, Secondary Prevention, Tertiary Prevention, Humans, Risk Reduction Behavior, Article
Abstract

Rheumatic diseases affect a significant portion of the population and lead to increased health care costs, disability and even premature mortality; as such, effective preventive measures for these diseases could lead to substantial improvements in public health. Importantly, established and emerging data from natural history studies show that for most rheumatic diseases there is a period of ‘preclinical’ disease development during which abnormal biomarkers or other processes can be detected. These changes are useful to understand mechanisms of disease pathogenesis; in addition, they may be applied to estimate a personal risk of future disease, while individuals are still relatively asymptomatic. Based on this, a hope is to implement effective screening and preventive approaches for some rheumatic diseases, perhaps in the near future. However, a key part of such approaches is a deep understanding of the mechanisms of disease development as well as evidence-based and effective screening and preventive interventions that incorporate disease biology as well as ethical and public health concerns.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results